Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8359134 | Prostaglandins & Other Lipid Mediators | 2018 | 25 Pages |
Abstract
Little is currently known of the role(s) of the vasoconstrictor 20-hydroxyeicosatetraenoic acid (20-HETE) in hypertensive pregnancies. We hypothesized that specific inhibition of 20-HETE would attenuate increases in blood pressure in the reduced uterine perfusion pressure (RUPP) rat model of preeclampsia. Specific 20-HETE synthesis inhibitor HET0016 (1Â mg/kg) was administered daily to RUPP rats from gestational days 14-18. Blood pressure (BP) increased in RUPP rats and was decreased with HET0016 administration. BP was unchanged in NPÂ +Â HET0016 rats. Fetal death greatly increased in RUPP rats and was reduced in RUPPÂ +Â HET0016 rats. 20-HETE levels increased modestly in RUPP rats compared to NP and was reduced in both NPÂ +Â HET0016 and RUPPÂ +Â HET0016 rats. Furthermore, circulating levels of HETEs, EET, and DHETE were significantly altered between groups. HET0016 shifted CYP metabolism toward EETs, as indicated by a decrease in plasma 20-HETE:EETs in RUPPÂ +Â HET0016 rats compared to RUPP. In conclusion, 20-HETE inhibition in RUPP rats reduces BP and fetal death, and is associated with an increase in EET/20-HETE ratio.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Jessica L. Faulkner, Nicole L. Plenty, Kedra Wallace, Lorena M. Amaral, Mark W. Cunningham, Sydney Murphy, Babbette LaMarca,